TG Therapeutics (TGTX) Stock Price, News & Analysis

Company Overview

TG Therapeutics, Inc. is a clinical‐stage biopharmaceutical company headquartered in New York City that specializes in developing targeted therapies for hematological malignancies and autoimmune diseases. The company’s research strategy focuses on the modulation of B-cell biology through novel antibody and small‐molecule agents. Since its founding in 2003, TG Therapeutics has built a diversified portfolio aimed at addressing unmet medical needs in oncology and immunology.

In December 2022, TG Therapeutics achieved its first commercial milestone when ublituximab-xiiy (marketed as Briumvi® in collaboration with Biogen) received U.S. Food and Drug Administration approval for the treatment of relapsing forms of multiple sclerosis. Earlier, in February 2021, the company’s selective PI3Kδ inhibitor umbralisib (UKONIQ®) was granted accelerated approval by the FDA for relapsed marginal zone lymphoma and follicular lymphoma. These regulatory achievements underscore TG’s ability to advance candidates from discovery through critical review.

The company’s pipeline extends beyond its approved therapies to include next‐generation anti-CD20 antibodies, such as TG-1701, and novel PI3K inhibitors designed to improve safety and efficacy profiles. Additional programs in clinical development target complementary pathways in B-cell malignancies and autoimmune disorders. TG Therapeutics conducts multi‐center trials across North America and Europe to evaluate these assets in a range of disease settings, with an emphasis on optimizing combination regimens and identifying patient subgroups most likely to benefit.

Guided by a management team with deep experience in oncology drug development and regulatory affairs, TG Therapeutics leverages strategic partnerships, in‐house research capabilities and contract research organizations to accelerate its clinical programs. The company’s operations span discovery, translational research and late‐stage development, positioning it to address both rare and prevalent immune‐mediated diseases on a global scale.

Key Stats

• Today's Range: $47.96 to $49.95
• 50-Day Range: $33.39 to $48.05
• 52-Week Range: $25.28 to $49.95
• Volume: 830,753 shs
• Average Volume: 2.08 million shs
• Market Capitalization: $7.64 billion
• P/E Ratio: 17.44
• Dividend Yield: N/A
• Price Target: $52.50
• Consensus Rating: Moderate Buy

TG Therapeutics Stock Analysis - MarketRank™

TG Therapeutics scored higher than 49% of companies evaluated by MarketBeat, and ranked 547th out of 863 stocks in the medical sector. Scores are calculated by averaging available category scores, with extra weight given to analysis and valuation.

Analyst's Opinion

• Score: 2.6 / 5
• Analyst Rating: Moderate Buy

Consensus Rating

TG Therapeutics has received a consensus rating of Moderate Buy. The company's average rating score is 2.71, and is based on 1 strong buy rating, 3 buy ratings, 3 hold ratings, and no sell ratings.

Upside/Downside

The consensus price target for TG Therapeutics is close to its current price, suggesting limited near-term upside or downside.

Amount of Analyst Coverage

TG Therapeutics has only been the subject of 3 research reports in the past 90 days.

Earnings and Valuation

• Score: 3.1 / 5
• Proj. Earnings Growth: 82.12%

Earnings Growth

Earnings for TG Therapeutics are expected to grow by 82.12% in the coming year, from $1.51 to $2.75 per share.

Price to Earnings Ratio vs. the Market

The P/E ratio of TG Therapeutics is 16.92, which means that it is trading at a less expensive P/E ratio than the market average P/E ratio of about 38.88.

Price to Earnings Ratio vs. Sector

The P/E ratio of TG Therapeutics is 16.92, which means that it is trading at a less expensive P/E ratio than the Medical sector average P/E ratio of about 24.17.

Price to Book Value per Share Ratio

TG Therapeutics has a P/B Ratio of 11.90. P/B Ratios above 3 indicate that a company could be overvalued with respect to its assets and liabilities.

Short Interest

• Score: 0.0 / 5
• Short Interest Level: Bearish

Percentage of Shares Shorted

20.60% of the float of TG Therapeutics has been sold short.

Short Interest Ratio / Days to Cover

TG Therapeutics has a short interest ratio ("days to cover") of 21.57, which indicates bearish sentiment.

Change versus previous month

Short interest in TG Therapeutics has recently increased by 0.27%, indicating that investor sentiment is decreasing.

Dividend

• Score: 0.0 / 5
• Dividend Strength: N/A

Dividend Yield

TG Therapeutics does not currently pay a dividend.

Dividend Growth

TG Therapeutics does not have a long track record of dividend growth.

News and Social Media

• Score: 2.3 / 5
• News Sentiment: 0.62

News Sentiment

TG Therapeutics has a news sentiment score of 0.62. This score is calculated as an average of sentiment of articles about the company over the last seven days and ranges from 2 (good news) to -2 (bad news). This is a lower news sentiment than the 0.78 average news sentiment score of Medical companies.

News Coverage This Week

MarketBeat has tracked 12 news articles for TG Therapeutics this week, compared to 5 articles on an average week.

Search Interest

Only 13 people have searched for TGTX on MarketBeat in the last 30 days. This is a decrease of -32% compared to the previous 30 days.

MarketBeat Follows

Only 5 people have added TG Therapeutics to their MarketBeat watchlist in the last 30 days. This is a decrease of 0% compared to the previous 30 days.

Company Ownership

• Score: 1.1 / 5
• Insider Trading: N/A

Insider Buying vs. Insider Selling

In the past three months, TG Therapeutics insiders have not sold or bought any company stock.

Percentage Held by Insiders

10.64% of the stock of TG Therapeutics is held by insiders. A high percentage of insider ownership can be a sign of company health.

Percentage Held by Institutions

58.58% of the stock of TG Therapeutics is held by institutions. High institutional ownership can be a signal of strong market trust in this company.

Company Calendar

• Last Earnings: 5/06/2026
• Today: 6/12/2026
• Next Earnings (Estimated): 8/03/2026
• Fiscal Year End: 12/31/2026

Industry, Sector and Symbol

• Stock Exchange: NASDAQ
• Sector: Medical
• Industry: MED - BIOMED/GENE
• Sub-Industry: Pharmaceutical Products
• Current Symbol: NASDAQ:TGTX
• Previous Symbol: OTCMKTS:TGTX
• CIK: 1001316
• Web: www.tgtherapeutics.com
• Phone: (212) 554-4484
• Fax: 212-554-4531
• Employees: 290
• Year Founded: 1993

Price Target and Rating

• Average Price Target for TG Therapeutics: $52.50
• High Price Target: $70.00
• Low Price Target: $39.00
• Potential Upside/Downside: +5.2%
• Consensus Rating: Moderate Buy
• Rating Score (0-4): 2.71
• Research Coverage: 7 Analysts

Profitability

• EPS (Trailing Twelve Months): $2.86
• Trailing P/E Ratio: 17.44
• Forward P/E Ratio: 33.04
• P/E Growth: N/A
• Net Income: $447.18 million
• Net Margins: 65.95%
• Pretax Margin: 17.46%
• Return on Equity: 88.73%
• Return on Assets: 43.44%

Debt

• Debt-to-Equity Ratio: 1.28
• Current Ratio: 5.81
• Quick Ratio: 5.12

Sales & Book Value

• Annual Sales: $616.29 million
• Price / Sales: 12.39
• Cash Flow: $3.00 per share
• Price / Cash Flow: 16.64
• Book Value: $4.08 per share
• Price / Book: 12.23

Miscellaneous

• Outstanding Shares: 153,080,000
• Free Float: 136,796,000
• Market Cap: $7.64 billion
• Optionable: Optionable
• Beta: 1.68